Delivery Order SPE2DB22D3301-SPE2DB25FZ0EV
- Not listed
- The Defense Logistics Agency awarded a $5,167.20 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a purchase order for a respiratory medication commonly used in the treatment of cystic fibrosis and is being delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. The contract was awarded on...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) at a ceiling value of $6,286.98. This firm fixed-price delivery order, with an ultimate completion date of July 24, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor. The performance location is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,533.25 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. The contract was competitively awarded on August 12, 2025, under a firm fixed-price arrangement with an ultimate completion date of August 13, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on August 25, 2025, with a ceiling value of $24,334.03 and ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply delivery under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,348.64 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in respiratory treatment. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. This firm fixed price contract, valued at $5,167.20, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency awarded a $9.68K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampules (2.5 mL units) on July 23, 2025, with completion expected by July 24, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M vehicle extending through...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $6,018.36 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml units) on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract employs firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL pharmaceutical product. This is a firm fixed price delivery order with a ceiling value of $2,583.60 and an ultimate completion date of July 28, 2025. The contract was awarded without a set-aside designation through competitive procurement, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. This...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0EVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product commonly used in cystic fibrosis treatment. This non-set-aside, firm fixed-price delivery order has a ceiling value of $16,287.62 and an ultimate completion date of August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains significant federal contracting relationships with the Defense Logistics Agency's Medical Supply Chain. The company's extensive portfolio demonstrates capability in supplying a wide range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military and veteran healthcare systems. This specific delivery order represents a routine transaction within AmerisourceBergen's broader pharmaceutical prime vendor relationship, enabling the Defense Health Agency and other government healthcare systems to access critical medications through a flexible contract vehicle designed to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.3k | 8/28/25 |